Recognized standard
F756-17
FDA recognition 2-250 · ASTM · Biocompatibility
Key facts
| Recognition number | 2-250 |
|---|---|
| Designation | F756-17 |
| Title | Standard Practice for Assessment of Hemolytic Properties of Materials |
| Standards developer | ASTM International |
| Specialty area | Biocompatibility |
| Date of entry | Jun 7, 2018 |
| Scope (excerpt) | 1.1 This practice provides a protocol for the assessment of hemolytic properties of materials used in the fabrication of medical devices that will contact blood. 1.2 This practice is intended to evaluate the acute in vitro hemolytic properties of materials intended for use in contact with blood. 1.3… |
At a glance
- None Product codes
- 1–9 FDA guidance documents
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA-recognized consensus standards
The FDA recognizes voluntary consensus standards that manufacturers can cite in premarket submissions to show conformity with specific requirements.
Source: U.S. Food and Drug Administration (FDA), Recognized Consensus Standards database · Source date: